Compare INDP & CIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INDP | CIX |
|---|---|---|
| Founded | 2000 | 1993 |
| Country | United States | United States |
| Employees | N/A | 549 |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 438.4M | 425.6M |
| IPO Year | 2021 | 1997 |
| Metric | INDP | CIX |
|---|---|---|
| Price | $3.07 | $35.15 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 451.9K | 11.1K |
| Earning Date | 11-11-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 6.38% |
| EPS Growth | N/A | ★ 17.04 |
| EPS | N/A | ★ 1.06 |
| Revenue | N/A | ★ $158,285,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $32.42 |
| Revenue Growth | N/A | ★ 8.46 |
| 52 Week Low | $0.92 | $20.29 |
| 52 Week High | $5.96 | $40.30 |
| Indicator | INDP | CIX |
|---|---|---|
| Relative Strength Index (RSI) | 55.54 | 46.25 |
| Support Level | $2.05 | $23.52 |
| Resistance Level | $3.75 | $40.30 |
| Average True Range (ATR) | 0.33 | 1.60 |
| MACD | 0.03 | -0.53 |
| Stochastic Oscillator | 78.48 | 42.26 |
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
Compx International Inc is a manufacturer of security products. Its security products are used in recreational transportation, postal, office & institutional furniture, cabinetry, tool storage, healthcare, and a variety of other industries. Also, it is engaged in the manufacturing of stainless steel exhaust systems, gauges, throttle controls, and trim tabs for the recreational marine industry. The company's reportable operating segment includes Security Products and Marine Components. It generates maximum revenue from the Security Products segment, which manufactures mechanical and electrical cabinet locks and other locking mechanisms. Geographically, the company generates maximum revenue from the United States, followed by Canada, Mexico, and other markets.